syncsulin® empowers people with diabetes to live with fewer complications, enhanced daily well-being, and greater independence through intelligent, predictive technologies.
Founded in 2025, syncsulin® is a German MedTech startup that envisions a future in which every person with Type 1 diabetes has access to an intuitive, intelligent, and seamlessly connected system that supports their health. Building on this foundation, syncsulin® seeks to advance AI-supported digital healthcare and to help shape the future of connected, patient-centered medicine.
Meet the team
Alessandro Dani, PhD
Co-Founder
Alessandro holds a PhD in Chemistry and brings a deep passion for science to his role as the visionary founder of syncsulin. He is committed to applying a scientific approach to blood sugar regulation and strives to create a product that supports people with diabetes in making informed decisions about their health.
He brings over a decade of experience in both large companies and innovative start-ups, having held leadership roles including Chief Commercial Officer and Head of Business Development. Driven by creativity and a relentless pursuit of better solutions, he leads product development, research, and scientific validation, leveraging predictive AI to transform diabetes care and make advanced, intelligent diabetes management accessible to everyone.
Michael Munsch
Co-Founder
As Co-Founder of syncsulin, Michael is responsible for the company’s commercial and legal strategy as well as for building strong market and distribution partnerships. Driven by a passion for creating meaningful solutions, he combines a deep understanding of business strategy with a strong legal foundation - shaped by his studies at a leading business school and years of advising technology companies and start-ups.
Michael ensures that syncsulin’s innovations are developed on a solid and compliant foundation. His expertise spans commercial, IP, IT, and regulatory law, providing the framework that allows innovation to thrive safely and sustainably. Above all, his work is guided by the mission to make life with diabetes simpler, safer, and more predictable for millions of people.